December 21, 2018, New York, NY — Americord Registry, LLC, a leading cord blood, cord tissue, and placental tissue bank, announced today the launch of its new website. The layout and functionality have been optimized for an improved user-experience that better serves Americord’s customers and individuals seeking more education about stem cell banking services. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Cesca Therapeutics Receives 510(k) Clearance to Market Its AXP® II AutoXpress® Platform for Clinical Cord Blood Banking
RANCHO CORDOVA, Calif., Nov. 19, 2018— Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that its device subsidiary, ThermoGenesis® Corp., has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its proprietary AXP® II AutoXpress® Platform (AXP II) for clinical blood banking.
The AXP II, in combination with the Company’s companion, single-use, cell separation set provides automated, rapid and reliable harvest of stem and progenitor cells from collected units of umbilical cord blood in a “functionally-closed” sterile system. [Read more…]
HemaCare Provides Starting Material for All Three FDA Approved Immunotherapies
HemaCare Corporation (OTCMKTS: HEMA) is a long-standing leader in the customization and supply of human-derived biological products and services for biomedical research and cell therapy. Within the U.S. and internationally, the company is well-known for its network of FDA-registered, GMP/GTP-compliant collection centers where it collects human biological materials. Types of cellular materials collected and supplied by Hemacare include peripheral blood, bone marrow, and cord blood, each of which it isolates into primary cells types and can supply to customers in both fresh and frozen states. [Read more…]
The Market for Cord Blood and Tissue Banking in China
China represents a unique and compelling market for cord blood and tissue banking. First, the Chinese government only supports one cord blood bank within each of the provinces. Specifically, the Chinese government issues one cord blood banking license per province, and the licensed company must function as hybrid “public and private” bank.
The private, for-profit division of the company is expected to fund the company’s public, donation-based division, because no government support is given to support its processing and storage of donated units.
In this article:
Arizona-based biotech startup BioLab Sciences announces patent for regenerative tissue therapy, MyOwn Skin™
SCOTTSDALE, Ariz., Oct. 24, 2018 — BioLab Sciences, an innovator in regenerative medicine technologies, today announced its exclusively licensed technology for MyOwn SkinTM, a painless, non-surgical procedure, which leverages a patient’s own skin to produce full-thickness skin grafts in 5-7 days.
MyOwn SkinTM is a revolutionary approach that uses a patient’s own skin to accelerate healing of chronic wounds, burns, diabetic foot ulcers and other difficult-to-heal wounds. By utilizing a small skin sample, this regenerative approach allows the body to heal itself and is less likely to face infection or rejection. [Read more…]
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 62
- Next Page »